ILEX MEDICAL LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,420 ILa | +0.19% |
|
-4.16% | +9.18% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 525.8 | 835.9 | 1,388 | 1,834 | 1,081 | 663.3 |
| Enterprise Value (EV) 1 | 505.8 | 845.5 | 1,279 | 1,608 | 906.8 | 494.5 |
| P/E ratio | 11.2 x | 13.9 x | 10.9 x | 9.29 x | 10.6 x | 12.9 x |
| Yield | 4.75% | - | 4.32% | 3.27% | 2% | 2.32% |
| Capitalization / Revenue | 0.87 x | 1.32 x | 1.47 x | 1.73 x | 1.24 x | 0.71 x |
| EV / Revenue | 0.84 x | 1.33 x | 1.35 x | 1.52 x | 1.04 x | 0.53 x |
| EV / EBITDA | 5.12 x | 8.5 x | 7.32 x | 5.66 x | 5.18 x | 4.65 x |
| EV / FCF | 22.4 x | 23.8 x | 11.5 x | 9.54 x | 29 x | 14.6 x |
| FCF Yield | 4.47% | 4.2% | 8.68% | 10.5% | 3.45% | 6.85% |
| Price to Book | 2.77 x | 3.75 x | 3.13 x | 3.19 x | 1.76 x | 1.06 x |
| Nbr of stocks (in thousands) | 10,035 | 10,035 | 11,281 | 11,281 | 11,281 | 11,281 |
| Reference price 2 | 52.40 | 83.30 | 123.0 | 162.6 | 95.82 | 58.80 |
| Announcement Date | 26/03/19 | 30/03/20 | 15/03/21 | 15/03/22 | 23/03/23 | 28/03/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 601.1 | 634 | 946.5 | 1,061 | 872.5 | 930.9 |
| EBITDA 1 | 98.86 | 99.42 | 174.6 | 284.2 | 175.2 | 106.4 |
| EBIT 1 | 75.17 | 75.76 | 146.5 | 246.1 | 138.9 | 72.85 |
| Operating Margin | 12.5% | 11.95% | 15.48% | 23.2% | 15.92% | 7.83% |
| Earnings before Tax (EBT) 1 | 67.5 | 85.48 | 153.8 | 255.3 | 136.7 | 69.4 |
| Net income 1 | 46.98 | 60.26 | 120.6 | 197.5 | 102.1 | 50.88 |
| Net margin | 7.82% | 9.5% | 12.74% | 18.61% | 11.7% | 5.47% |
| EPS 2 | 4.682 | 6.005 | 11.24 | 17.50 | 9.050 | 4.547 |
| Free Cash Flow 1 | 22.62 | 35.55 | 110.9 | 168.6 | 31.28 | 33.87 |
| FCF margin | 3.76% | 5.61% | 11.72% | 15.89% | 3.58% | 3.64% |
| FCF Conversion (EBITDA) | 22.88% | 35.76% | 63.53% | 59.32% | 17.85% | 31.84% |
| FCF Conversion (Net income) | 48.14% | 59% | 91.96% | 85.36% | 30.63% | 66.56% |
| Dividend per Share 2 | 2.491 | - | 5.319 | 5.319 | 1.917 | 1.364 |
| Announcement Date | 26/03/19 | 30/03/20 | 15/03/21 | 15/03/22 | 23/03/23 | 28/03/24 |
1ILS in Million2ILS
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 9.59 | - | - | - | - |
| Net Cash position 1 | 20 | - | 109 | 226 | 174 | 169 |
| Leverage (Debt/EBITDA) | - | 0.0965 x | - | - | - | - |
| Free Cash Flow 1 | 22.6 | 35.5 | 111 | 169 | 31.3 | 33.9 |
| ROE (net income / shareholders' equity) | 18.6% | 20.9% | 32.8% | 38.8% | 17.2% | 8.23% |
| ROA (Net income/ Total Assets) | 9.23% | 8.49% | 13.5% | 18.6% | 9.78% | 4.75% |
| Assets 1 | 509.2 | 709.6 | 896.5 | 1,062 | 1,044 | 1,070 |
| Book Value Per Share 2 | 18.90 | 22.20 | 39.30 | 51.00 | 54.50 | 55.70 |
| Cash Flow per Share 2 | 5.560 | 5.020 | 14.20 | 23.00 | 17.90 | 13.30 |
| Capex 1 | 24.1 | 29.9 | 44.3 | 40.9 | 26.1 | 48.8 |
| Capex / Sales | 4% | 4.72% | 4.68% | 3.86% | 3% | 5.24% |
| Announcement Date | 26/03/19 | 30/03/20 | 15/03/21 | 15/03/22 | 23/03/23 | 28/03/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +9.18% | 195M | |
| -13.42% | 275M | |
| +26.13% | 77.74M | |
| +18.43% | 65.31M |
- Stock Market
- Equities
- ILX Stock
- Financials Ilex Medical Ltd
